Targeting BLyS in rheumatic disease: The sometimes-bumpy road from bench to bedside

Current Opinion in Rheumatology

Volumn 23, Issue 3, 2011, Pages 305-310

  Stohl, William ^a   Scholz, Jean L ^b   Cancro, Michael P ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell targeted therapy; BAFF; BLyS; lupus; SLE

Indexed keywords

A 623; ANTIRHEUMATIC AGENT; ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; LY 2127399; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECOMBINANT FUSION PROTEINS; RHEUMATIC DISEASES; TRANSLATIONAL RESEARCH;

EID: 79955035677     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328344c15e     Document Type: Review

References (44)

1. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066-1073.
2. Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006; 176:6405-6410. (Pubitemid 43787821)
3. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10:R109.
4. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168-1178.
5. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61:1143-1151.
6. Navarra S, Guzman R, Gallacher A, et al., BLISS-52 Study Group. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Arthritis Rheum 2009; 60:3859.
7. Furie R, Zamani O, Wallace D, et al., BLISS-76 Study Group. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. Arthritis Rheum 2010; 62:S606.
8. Merrill JT, Wallace DJ, Furie RA, et al.; LBSL02/99 Study Group. Five-year experience with belimimab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2010; 62(Suppl 10):1457.
9. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142-4150. (Pubitemid 350262342)
10. Stohl W, Merrill JT, Looney RJ, et al. Phase 1a single-and phase 1b multipledose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus (SLE). Arthritis Rheum 2008; 58:S565-S566.
11. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009; 53:1-16.
12. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20:785-798. (Pubitemid 38757447)
13. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigenengaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441-453. (Pubitemid 38482122)
14. Hondowicz BD, Alexander ST, Quinn WJ 3rd, et al. The role of BLyS/BLyS receptors in antichromatin B cell regulation. Int Immunol 2007; 19:465-547.
15. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199:91-98.
16. Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18:279-288. (Pubitemid 36263002)
17. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRILdeficient mice. Proc Natl Acad Sci USA 2004; 101:3903-3908. (Pubitemid 38381075)
18. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006; 18:305-317. (Pubitemid 44287555)
19. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010; 22:732-739.
20. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006; 18:290-296. (Pubitemid 44382641)
21. Sakurai D, Hase H, Kanno Y, et al. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2006; 109:2961-2967. (Pubitemid 46482094)
22. Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008; 105:15517-15522.
23. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180:3655-3659.
24. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cellactivating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778-785.
25. Ettinger R, Sims GP, Robbins R, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007; 178:2872-2882. (Pubitemid 46333165)
26. Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immunebased rheumatic diseases. J Immunol 2002; 169:4314-4321. (Pubitemid 35178204)
27. Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1065-1067. (Pubitemid 40909524)
28. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166:6-10. (Pubitemid 32038409)
29. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 2010; 12:111-112.
30. Zhao LD, Li Y, Smith MF Jr, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010; 19:1534-1549.
31. Treml LS, Quinn WJ 3rd, Treml JF, et al. Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz) 2008; 56:153-164.
32. Ramanujam M, Bethunaickan R, Huang W, et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010; 62:1457-1468.
33. Ding H, Wang L, Wu X, et al. Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J Cell Mol Med 2010; 14:1717-1725.
34. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48:3253-3265. (Pubitemid 37409340)
35. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood b-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci 2006; 91:586-599. (Pubitemid 43827311)
36. Auyeung-Kim DJ, Devalaraja MN, Migone TS, et al. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol 2009; 28:443-455.
37. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999. (Pubitemid 30243593)
38. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724-734. (Pubitemid 43326881)
39. Manzi S, Sanchez-Guerrero J, Merrill JT, et al., BLISS-52 and -76 Study Groups. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase .3. BLISS-52 and -76 studies. Arthritis Rheum 2010; 62 (Suppl 10):1456.
40. Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 2008; 105: 200-210.
41. Stohl W, Hiepe F, Thomas M, et al., BLISS-52 and -76 Study Groups. Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the phase 3 BLISS studies. Arthritis Rheum 2010; 62 (Suppl 10): 1146.
42. Kikly K, Manetta J, Smith H, et al. Characterization of LY2127399, a neutralizing antibody for BAFF [abstract]. Arthritis Rheum 2009; 60 (Suppl 10):693.
43. Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; 45:144-158.
44. Looney RJ, Anolik J, Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010; 20:1-10.